A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Nutrition Journal

Lidia Alfaro Brownell²  John S Sampalis¹ 

[1] Surgery and Epidemiology McGill University and Universite du Montreal, Montreal, Quebec, Canada;Unigen Inc., 2260 Willamette Drive NE, 98516 Lacey, Washington, USA

关键词: UP446;    LOX;    COX-2;    Anti-inflammatory;    NSAIDs;   

Others  :  825746
DOI  :  10.1186/1475-2891-11-21

 received in 2011-01-27, accepted in 2012-04-05,  发布年份 2012

【 摘 要 】

Background

Current use of prescribed or over the counter non-steroidal anti-inflammatory drugs (NSAIDs) for pain and osteoarthritis (OA) have untoward gastrointestinal and cardiovascular related side effects, as a result the need for a safe and effective alternative has become unequivocally crucial.

Method

A randomized, double blind, placebo and active controlled pilot study of a novel dual pathway, COX1/2 and LOX, inhibitor anti-inflammatory agent of botanical origin, UP446 was conducted. Sixty subjects (age 40-75) with symptomatic OA of the hip or knee were assigned to 4 treatment groups (n = 15); Group A0 (Placebo, CMC capsule), Group A1 (UP446 250 mg/day), Group A2 (UP446 500 mg/day) and Group A3 (Celecoxib, 200 mg/day). MOS-SF-36 and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) data were collected at baseline and after 30, 60 and 90 days of treatment as a measure of efficacy. Erythrocyte sedimentation rate, C-reactive protein, plasma thrombin time (PTT), fructosamine, Hematology, clinical chemistry and fecal occult blood were monitored for safety.

Results

Statistically significant decrease in WOMAC pain score were observed for Group A1 at day 90, Group A2 at 30 and 90 days and Group A3 at 60 and 90 days. Statistically significant decrease in WOMAC stiffness score were observed for Group A1 and Group A2 at 30, 60 and 90 days; but not for Group A0 and Group A3. The mean change in WOMAC functional impairment scores were statistically significant for Group A1 and Group A2 respectively at 30 days (p = 0.006 and p = 0.006), at 60 days (p = 0.016 and p = 0.002) and at 90 days (p = 0.018 and p = 0.002), these changes were not significant for Group A0 and Group A3. Based on MOS -SF-36 questionnaires, statistically significant improvements in physical function, endurance and mental health scores were observed for all active treatment groups compared to placebo. No significant changes suggestive of toxicity in routine hematologies, serum chemistries, liver enzymes or PTT were noted in any of the treatment groups.

Conclusion

Based on current findings UP446 is safe and efficacious alternative to established anti-inflammatory medications for alleviating OA symptoms as measured by the WOMAC Index.

【 授权许可】

   
2012 Sampalis and Brownell; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Felson DT: The course of osteoarthritis and factors that affect it. Rheum Clin North Am 1993, 19:607-615.
• [2]Zhang Y, et al.: Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly, The Framingham Study. Am J Epidemiol 2002, 156:1021-1027.
• [3]Felson , et al.: Osteoarthritis: New Insights: Part 1: The Disease and Its Risk Factors. Ann Intern Med 2000, 133(8):635-646.
• [4]Paredes Y, et al.: Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arth Rheum 2002, 46:1804-1812.
• [5]Garcia C, et al.: Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 1996, 11:1619-1627.
• [6]Rainsford KD: Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Agens Actions 1993, 39:C24-C26.
• [7]Rainsford KD, et al.: Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissue in organ culture: comparison with interleukin-1 synthesis inhibitors. J Pharm Pharmacol 1996, 48:46-52.
• [8]He W, Pelleier JP, Martel-Pelletier J, et al.: The synthesis of IL-1β, TNFα and interstitual collagenase (MMP-1) is eicosanoid dependent in human OA synovial membrane explants: interactions with anti-inflammatory cytokines. J Rheum 2002, 29:546-553.
• [9]Bertolini A, et al.: Dual acting anti-inflammatory drugs: A reappraisal. Pharmacol Res 2001, 44:437-450.
• [10]Van Loon IM: The golden root: clinical applications of Scutellaria baicalensi GEORGI flavanoids as modulators of the inflammatory response. Altern Med Rev 1997, 2:472-480.
• [11]Nakajima T, Imanishi M, Yamamoto K, Cyong JC, Hirai K: Inhibitory Effect of baicalein, a flavanoid in Scutellaria Root, on eostaxin production by human dermal fibroblasts. Planta Med 2001, 67:132-135.
• [12]Zhao S, et al.: Evaluation of the functional status aspects of health related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999, 19:1269-1278.
• [13]Thompson D, Pepys MB, Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999, 7(2):169-177.
• [14]Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111(12):1805-1812.
• [15]Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246.
• [16]Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288(5):H2031-H2041.
• [17]Laporte JR, et al.: Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti- inflammatory drugs. Lancet 1991, 337:85-89.
• [18]Ong CK, Lirk P, Tan CH, Seymour RA: An evidence based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007, 5:19-34.
• [19]Angst F, et al.: Ann Rheum Dis. 2001, 60:834-840.
• [20]Terwee CB, et al.: J Clin Epidem. 2006, 59:724-731.
• [21]Rockey DC: Occult Gastrointestinal Bleeding. Gastroenterol Clin North Am 2005, 34(4):699-718. 21
• [22]Beg M, et al.: Occult Gastrointestinal Bleeding: Detection, Interpretation, and Evaluation. JIACM 2002, 3(2):153-158.